A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2013
At a glance
- Drugs Sorafenib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Early breast cancer
- Focus Adverse reactions
- 02 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 02 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2008 Status changed from recruiting to in progress.